Abstract 1857P
Background
The COVID-19 pandemic has been closely associated with a decline in mental health. The goal of this study was to identify the degree of distress of cancer patients before and after the pandemic and to find out if COVID-19 worsened the mental health of cancer patients.
Methods
A self-rated survey was conducted for 2 groups of patients at The Todua Clinic, Tbilisi, Georgia twice: at the peak of pandemic and again 6 months after the pandemic. Study included adult cancer patients, with solid tumors, over 18 years of age, receiving chemotherapy, being able to understand and answer the questions in written English. Event Scale-Revised (IES-R) test was implemented to measure Post-Traumatic Stress Disorder (PTSD). Total IES-R score of 33 or over signifies the likely presence of PTSD.
Results
Study enrolled total of 195 patients, 103 patients - during and 92 - after the pandemic. 3 independent and 5 dependent variables were created. Independent variables were: 1. IES-R score ≥24 ( y=1 if score ≥ 24, y=0 if score ≤ 24); 2. IES-R score≥ 33 (y=1 if score ≥ 33, y=0 if score ≤ 33); 3. IES-R score 37 (y= 1 if score ≤ 37, y=0 f score ≤ 37). Five dependent variables were: time, type of disease, stage, sex, and marital status. We created 3 regression models with independent and dependent variables (model 1: independent variable was IES-R score ≥24, model 2 independent variable was - IES-R score ≥ 33, model 3 IES-R score ≥ 33). We observed improvement in IES-R scores in the post-pandemic period: In model 1 - results improved by 20%, In model 2 - 16%, and in model 3 – 14%. Female and married individuals had better results in both periods. We calculated the data and observed that all dependent variables other than the disease type and the disease stage had a significant impact on IES-R scores.
Conclusions
Our findings showed a significant difference in IES-R scores in patients before and after the COVID-19 pandemic, with notable improvement in the post-COVID period. We also observed that sex, disease stage, marital status, and disease stage affected IES-R scores. We conclude that COVID-19 worsened the mental health of cancer patients. Our study highlighted the need for efforts to better integrate psychosocial support into cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05